Gsa Capital Partners LLP Astria Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 30,928 shares of ATXS stock, worth $205,671. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,928
Previous 67,174
53.96%
Holding current value
$205,671
Previous $359,000
53.76%
% of portfolio
0.01%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding ATXS
# of Institutions
118Shares Held
51.7MCall Options Held
7KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$43.1 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$33.9 Million0.57% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$27.8 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$27.3 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$23.6 Million6.47% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $101M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...